Published online June 1, 2006
PEDIATRICS Vol. 117 No. 6 June 2006, pp. e1087-e1094 (doi:10.1542/10.1542/peds.2005-2651)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garbutt, J.
Right arrow Articles by Storch, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garbutt, J.
Right arrow Articles by Storch, G. A.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Empiric First-line Antibiotic Treatment of Acute Otitis in the Era of the Heptavalent Pneumococcal Conjugate Vaccine

Jane Garbutt, MB, ChBa,b, Isabel Rosenbloom, MDb, Jenny Wua and Gregory A. Storch, MDb

a Division of General Medical Sciences
b Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri

OBJECTIVES. Our goal was to estimate the local prevalence of Streptococcus pneumoniae nonsusceptible to penicillin and amoxicillin after widespread use of the heptavalent pneumococcal vaccine and to revise community-specific recommendations for first-line antibiotic treatment of acute otitis media.

METHODS. We conducted serial prevalence surveys between 2000 and 2004 in the offices of community pediatricians in St Louis, Missouri. Study participants were children <7 years of age with acute upper respiratory infections. Children treated with an antibiotic in the past 4 weeks were excluded. S pneumoniae was isolated from nasopharyngeal swabs using standard techniques. Isolates with a penicillin minimum inhibitory concentration >2 µg/mL were considered to be S pneumoniae nonsusceptible to amoxicillin.

RESULTS. There were 327 patients enrolled in the study. Between 2000 and 2004, vaccine coverage with ≥3 doses of heptavalent pneumococcal vaccine increased from 0% to 54%, but nasopharyngeal carriage of S pneumoniae was stable at 39%. The prevalence of S pneumoniae nonsusceptible to penicillin fell from 25% to 12% among patients, did not vary if <2 years of age, was reduced in children with ≥3 doses of heptavalent pneumococcal vaccine, and increased in child care attendees but reduced in attendees who had ≥3 doses of heptavalent pneumococcal vaccine. The prevalence of S pneumoniae nonsusceptible to amoxicillin in patients remained <5%.

CONCLUSIONS. In our community, widespread use of heptavalent pneumococcal vaccine has reduced the prevalence of S pneumoniae nonsusceptible to penicillin, and the prevalence of S pneumoniae nonsusceptible to amoxicillin remains low (<5%). If antibiotic treatment is elected for children with uncomplicated acute otitis media, we recommend treatment with standard-dose amoxicillin (40–45 mg/kg per day) for children with ≥3 doses of heptavalent pneumococcal vaccine, regardless of age and child care status. High-dose amoxicillin should be used for children with <3 doses of heptavalent pneumococcal vaccine and those treated recently with an antibiotic.

Key Words: Streptococcus pneumoniae • acute otitis media • conjugated pneumococcal vaccine • treatment guidelines

Abbreviations: AOM—acute otitis media • MIC—minimum inhibitory concentration • NSSP—Streptococcus pneumoniae nonsusceptible to penicillin • NSSP-A—Streptococcus pneumoniae nonsusceptible to amoxicillin • PCV7—heptavalent pneumococcal conjugate vaccine • CI—confidence interval • OR—odds ratio

Accepted Dec 14, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
M. E. Pichichero and J. R. Casey
Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in Children
JAMA, October 17, 2007; 298(15): 1772 - 1778.
[Abstract] [Full Text] [PDF]